Search Results for "Chemotherapy"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Chemotherapy. Results 51 to 60 of 220 total matches.

Margetuximab (Margenza) for HER2-Positive Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
(Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy ...
The FDA has approved margetuximab-cmkb (Margenza – MacroGenics), a HER2/neu receptor antagonist, for use in combination with chemotherapy for treatment of metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer in adults who received ≥2 prior anti-HER2 regimens, at least one of which was for metastatic disease.
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e195-6 |  Show IntroductionHide Introduction

Mobocertinib (Exkivity) for Non-Small Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 28, 2022  (Issue 1664)
insertion mutations in adults whose disease has progressed on or after platinum-based chemotherapy ...
Mobocertinib (Exkivity – Takeda), an oral kinase inhibitor, has received accelerated approval from the FDA for treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 20 insertion mutations in adults whose disease has progressed on or after platinum-based chemotherapy. Accelerated approval was based on the overall response rate and duration of response. Mobocertinib is the second drug to become available in the US for this indication; the IV EGFR-MET bispecific antibody amivantamab (Rybrevant) was approved...
Med Lett Drugs Ther. 2022 Nov 28;64(1664):e197-8 |  Show IntroductionHide Introduction

PARP Inhibitors for Ovarian Cancer

   
The Medical Letter on Drugs and Therapeutics • Dec 04, 2017  (Issue 1535)
, recurrent ovarian, primary peritoneal, or fallopian tube cancer who had received ≥3 lines of chemotherapy ...
Three oral poly(ADP-ribose) polymerase (PARP) inhibitors have been approved by the FDA for treatment of advanced, recurrent ovarian cancer. Olaparib (Lynparza – AstraZeneca), niraparib (Zejula – Tesaro), and rucaparib (Rubraca – Clovis) are each approved for somewhat different indications and for patients with different biomarkers (see Table 2).
Med Lett Drugs Ther. 2017 Dec 4;59(1535):200-2 |  Show IntroductionHide Introduction

Lurbinectedin (Zepzelca) for Small-Cell Lung Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy. Accelerated ...
The alkylating agent lurbinectedin (Zepzelca – Jazz) has received accelerated approval from the FDA for treatment of metastatic small-cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy. Accelerated approval was based on the overall response rate and duration of response. About 13-15% of lung cancers are small-cell cancers. Most SCLCs occur in patients who are current or former smokers.
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e198-9 |  Show IntroductionHide Introduction

Bone Marrow Transplants for Malignant Diseases

   
The Medical Letter on Drugs and Therapeutics • Aug 21, 1992  (Issue 877)
FOR ONLINE USERS BONE MARROW TRANSPLANTS FOR MALIGNANT DISEASES Intensive chemotherapy, with or without ...
Intensive chemotherapy, with or without total body radiation, followed by bone marrow transplantation is now widely used in the treatment of malignant diseases. The drugs and radiation needed to try to eradicate the malignancy unavoidably destroy the bone marrow; intravenous infusion of bone marrow cells restores the marrow by repopulating it. Diseases for which bone marrow transplantation has been used include the leukemias and lymphomas, breast cancer, neuroblastoma, ovarian cancer, germ cell tumors, melanoma, multiple myeloma, and malignant gliomas (NC Gorin, Am J Clin On-col, 14...
Med Lett Drugs Ther. 1992 Aug 21;34(877):79-80 |  Show IntroductionHide Introduction

A New Indication for Axicabtagene Ciloleucel (Yescarta) (online only)

   
The Medical Letter on Drugs and Therapeutics • Nov 14, 2022  (Issue 1663)
of diffuse large B-cell lymphoma, the most common type of non-Hodgkin's lymphoma, respond to chemotherapy ...
The FDA recently approved axicabtagene ciloleucel (Yescarta – Kite), a CD19-directed genetically modified cellular product, for treatment of large B-cell lymphoma that is refractory to first-line chemoimmunotherapy or that relapses within 12 months of first-line treatment. It was previously approved for treatment of relapsed or refractory B-cell lymphoma after ≥2 lines of systemic therapy and for treatment of relapsed or refractory follicular lymphoma after ≥2 lines of systemic therapy. Yescarta is an individualized cellular product prepared from the patient's own T cells,...
Med Lett Drugs Ther. 2022 Nov 14;64(1663):e194-5 |  Show IntroductionHide Introduction

In Brief: Phesgo - A Fixed-Dose Combination for HER-2 Positive Breast Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Mar 16, 2021  (Issue 1619)
in combination with chemotherapy for neoadjuvant (preoperative) treatment of human epidermal growth factor ...
The FDA has approved a fixed-dose combination of pertuzumab, trastuzumab, and hyaluronidase (Phesgo – Genentech) for use in combination with chemotherapy for neoadjuvant (preoperative) treatment of human epidermal growth factor receptor 2 (HER2)-positive, locally advanced, inflammatory, or early-stage breast cancer, or for adjuvant treatment of patients with HER2-positive early breast cancer at high risk of recurrence, or with docetaxel for treatment of those with HER2-positive metastatic breast cancer who have not received anti-HER2 therapy or chemotherapy for metastatic disease....
Med Lett Drugs Ther. 2021 Mar 16;63(1619):e1-2 |  Show IntroductionHide Introduction

In Brief: Afamitresgene Autoleucel (Tecelra) for Synovial Sarcoma (online only)

   
The Medical Letter on Drugs and Therapeutics • Oct 14, 2024  (Issue 1713)
treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy ...
Afamitresgene autoleucel (Tecelra – Adaptimmune), a melanoma-associated antigen A4 (MAGE-A4)-directed genetically modified autologous T-cell immunotherapy, has received accelerated approval from the FDA for one-time treatment of adults with unresectable or metastatic synovial sarcoma who received prior chemotherapy and are HLA-A*02:01P, -A*02:02P, -A*02:03P, or -A*02:06P positive and whose tumor expresses the MAGE-A4 antigen. It is the first gene therapy to be approved in the US for treatment of synovial sarcoma. Accelerated approval of the immunotherapy was based on the...
Med Lett Drugs Ther. 2024 Oct 14;66(1713):e169-70   doi:10.58347/tml.2024.1713i |  Show IntroductionHide Introduction

Erdafitinib (Balversa) for Urothelial Carcinoma (online only)

   
The Medical Letter on Drugs and Therapeutics • May 13, 2024  (Issue 1702)
or chemotherapy (docetaxel or vinflunine). After a median follow-up of 15.9 months, overall survival ...
Erdafitinib (Balversa – Janssen), an oral kinase inhibitor, has received full approval from the FDA for treatment of locally advanced or metastatic urothelial carcinoma in adults with susceptible FGFR3 (fibroblast growth factor receptor) genetic alterations who had disease progression on or after at least one prior line of systemic therapy. It is not recommended for use in patients who are eligible for but have not received prior PD-1 (programmed death receptor-1) or PD-L1 (programmed death-ligand 1) inhibitor therapy. Erdafitinib is the first oral FGFR kinase inhibitor to be...
Med Lett Drugs Ther. 2024 May 13;66(1702):e83-4   doi:10.58347/tml.2024.1702g |  Show IntroductionHide Introduction

In Brief: Intravenous Ondansetron (Zofran) 32 mg Withdrawn

   
The Medical Letter on Drugs and Therapeutics • Dec 24, 2012  (Issue 1406)
that the single 32-mg IV dose of ondansetron (Zofran, and generics) used for prevention of cancer chemotherapy ...
The FDA has announced that the single 32-mg IV dose of ondansetron (Zofran, and generics) used for prevention of cancer chemotherapy-associated nausea and vomiting has been withdrawn from the market because it can prolong the QT interval and could possibly cause a torsades de pointes cardiac arrhythmia. For this indication, the only recommended dose of IV ondansetron is 0.15 mg/kg (maximum 16 mg/dose) every 4 hours for 3 doses. There are no changes in the recommended dosing regimens for oral ondansetron or for IV ondansetron used for prevention of postoperative nausea and vomiting.Download...
Med Lett Drugs Ther. 2012 Dec 24;54(1406):104 |  Show IntroductionHide Introduction